ArticleNature communications2021

In vivo genome-wide CRISPR screen reveals breast cancer vulnerabilities and synergistic mTOR/Hippo targeted combination therapy.

Meiou Dai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.